KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Interest & Investment Income: 2018-2025

Historic Interest & Investment Income for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Sep 2025 value amounting to $3.3 million.

  • Aurinia Pharmaceuticals' Interest & Investment Income fell 22.29% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year decrease of 19.87%. This contributed to the annual value of $17.0 million for FY2024, which is 0.16% down from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Interest & Investment Income stood at $3.3 million, which was up 3.95% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Interest & Investment Income ranged from a high of $4.6 million in Q4 2023 and a low of $106,000 during Q3 2021.
  • Moreover, its 3-year median value for Interest & Investment Income was $4.1 million (2023), whereas its average is $4.0 million.
  • In the last 5 years, Aurinia Pharmaceuticals' Interest & Investment Income plummeted by 37.65% in 2021 and then skyrocketed by 2,568.81% in 2022.
  • Over the past 5 years, Aurinia Pharmaceuticals' Interest & Investment Income (Quarterly) stood at $109,000 in 2021, then skyrocketed by 2,568.81% to $2.9 million in 2022, then skyrocketed by 57.03% to $4.6 million in 2023, then fell by 12.70% to $4.0 million in 2024, then dropped by 22.29% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, $3.2 million for Q2 2025, and $3.6 million during Q1 2025.